摘要:
There are presented compounds of the formula wherein R6 and R7 is R4 and R5 or R5 and R6 together with the carbon atoms to which they are attached, form a ring as defined in the description and X1, X2, Y1 to Y4, R1 to R13 and n are as specified in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.
摘要:
The invention is concerned with novel piperazine amide derivatives of formula (I) wherein R1 to R11, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.
摘要:
The invention relates to compounds of formula (I): and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim 1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.
摘要:
The invention is concerned with novel hexafluoroisopropanol substituted ether derivatives of formula (I): wherein R1 to R3 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.
摘要:
The invention is concerned with novel heteroaryl carboxamides of formula (I) wherein A, R1, R2, X, Y, Z and m are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used for the treatment or prevention of thrombotic disorders.
摘要:
This invention relates to compounds of the formula I: wherein one of R6, R7 and R8 is and R1 to R15 and n are as defined in the description, and all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR δ and/or PPARα agonists.
摘要翻译:本发明涉及式I化合物:其中R 6,R 7和R 8中的一个是R 1和R 2, R 15和R 15如在说明书中所定义,以及所有对映异构体及其药学上可接受的盐和/或酯。 本发明还涉及含有这些化合物的药物组合物,其制备方法及其用于治疗和/或预防由PPARδ和/或PPARα激动剂调节的疾病的用途。
摘要:
A fuel cell includes a cathode-electrolyte-anode unit, and a perforated foil structure distributes fuel gas over an electrode surface thereof. Longitudinal axes of at least some of the holes forming perforations in the foil are inclined differently relative to the foil surface such that, near a fuel gas feed, the outlet openings of the holes facing the electrode are oriented at least slightly toward the area of the fuel gas outlet from the fuel cell. Near a fuel gas outlet, the inlet openings of the holes facing the electrode are oriented at least slightly to the area of the fuel gas feed. However, holes whose inlet openings facing away from the electrode are oriented toward the fuel gas feed, and holes whose outlet openings facing away from the electrode are oriented toward the fuel gas outlet, may also be arranged alternately side-by-side.
摘要:
This invention relates to compounds of the formula wherein one of R6, R7 or R8 is and all enantiomers and pharmaceutically acceptable salts and/or esters thereof as well as pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.
摘要:
The invention is concerned with vinylogous acids derivatives of formula (I) wherein A and R1 to R6 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit chymase and can be used as medicaments.
摘要:
The present invention provides compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4, A and n have the significance given in the specification. The compounds or their salts may be administered to a patient for treating non-insulin dependent diabetes mellitus.